Knoll Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Knoll Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.3M	Buy	1,150,400 +550,000	+92%	+$4.99M	5.27%	5
2026 Q1	$5.09M	Hold	600,400	–	–	2.82%	17
2025 Q4	$7.28M	Hold	600,400	–	–	3.34%	12
2025 Q3	$7.02M	Hold	600,400	–	–	3.76%	11
2025 Q2	$1.86M	Hold	600,400	–	–	1.32%	19
2025 Q1	$4.4M	Hold	600,400	–	–	2.86%	11
2024 Q4	$5.13M	Hold	600,400	–	–	3.3%	9
2024 Q3	$5.22M	Buy	600,400 +400,000	+200%	+$3.3M	2.42%	12
2024 Q2	$1.37M	Hold	200,400	–	–	0.92%	20
2024 Q1	$1.82M	Hold	200,400	–	–	1.13%	19
2023 Q4	$894K	Buy	200,400 +200,000	+50,000%	+$591K	0.74%	29
2023 Q3	$1.26K	Sell	400 -199,600	-100%	-$817K	﹤0.01%	37
2023 Q2	$1.03M	Hold	200,000	–	–	1.25%	14
2023 Q1	$1.5M	Buy	+200,000	New	+$950K	2.32%	10

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Knoll Capital Management's OCUL Position: Q2 2026 in Review

Knoll Capital Management increased its Ocular Therapeutix (OCUL) stake by 92% in Q2 2026, buying an estimated $4.99M and bringing the position to 1,150,400 shares worth $11.3M. The position accounts for 5.27% of the portfolio, ranked #5.

Knoll Capital Management first reported a position in OCUL in Q1 2023 and has held it in 14 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Knoll Capital Management held 1,150,400 shares of Ocular Therapeutix worth $11.3M as of Q2 2026.
Knoll Capital Management bought 550,000 Ocular Therapeutix shares in Q2 2026, an estimated $4.99M.
Ocular Therapeutix made up 5.27% of Knoll Capital Management's portfolio in Q2 2026, its #5 holding.
Knoll Capital Management first reported a position in Ocular Therapeutix in Q1 2023 and has held it in 14 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.